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Peroxisome proliferator carcinogenesis
remains a controversial subject among the
scientific community, in spite of the fact
that it has matured from infancy to adoles-
cence. "In the last 10 years, we've obtained a
significant amount ofinformation regarding
peroxisome proliferators and human risk
assessment," says James Popp, international
toxicology director at Sanofi-Winthrop. "A
decade ago, the discussion was based largely
on hypotheses and limited data. Today, our
discussions focus on a much broader body
ofscientific knowledge."
Peroxisomes are single-membrane cyto-
plasmic organelles that contain a fine gran-
ular matrix. Present in all mammalian cells
except red blood cells, peroxisomes carry
out peroxidative functions through oxidase
enzymes by metabolizing long-chain fatty
acids. The number of peroxisomes, their
size, and enzymatic profile vary by tissue
location. When exposed to certain chemi-
cals called "peroxisome proliferators," these
organelles readily multiply. To date, more
than 70 chemicals, ranging from hypolipi-
demic agents to phthalate ester plasticizers
to solvents and herbicides to dietary factors
and hormones, have been cited in the scien-
tific literature as peroxisome proliferators.
While these compounds seem to pro-
duce similar qualitative changes in rodent
liver cells, their quantitative response is
dose dependent and species specific.
Although the liver is the prime target of
peroxisome proliferators, morphological
and/or biochemical changes occur in sever-
al tissues including the testis, thyroid, kid-
ney, intestine, adrenal glands, brown adi-
pose tissue, and heart. Also, in addition to
liver tumors, a subset ofperoxisome prolif-
erators increase testicular and pancreatic
tumors in rats. Rodent hepatic cells,
though, are the most responsive to peroxi-
some proliferators and the most extensively
studied tissue.
Extensive experimental evidence proves
there is more than a casual link between
peroxisome proliferator-elicited hepato-
megaly (enlarged liver) and subsequent liver
tumors in rodents. This link, though, has
not been established in humans.
Peroxisome proliferators are among the
most extensively studied nongenotoxic car-
cinogens. Still, proposed peroxisome prolif-
erator mechanisms of action, including
oxidative stress, induction of hepatic cell
proliferation, and the role of the peroxi-
some proliferator-activated receptor
(PPAR), need to be sorted out. Until these
mechanisms ofrodent cancer induction are
fully elucidated, it will be difficult to assess
the health risk to humans.
Peroxisomal Pathways
Hepatic peroxisomes are usually round,
measuring between 0.5 and 1.0 microns.
Rodent hepatocytes can contain enormous
numbers ofperoxisomes. Liver peroxisomal
enzymes in rodents are induced within a
few hours to a few days after exposure to
peroxisome proliferators. The activity of
catalase, the marker enzyme for these
organelles, and urate oxidase, a key enzyme
in catabolism ofnitrogenous compounds in
rodents, increases nearly 2-fold; the fatty
acid beta-oxidation enzyme system can
increase 20- to 30-fold. Differential regula-
tion of genes encoding peroxisomal
enzymes, many known to be controlled by
PPAR, account for this difference in activi-
ty. Hepatomegaly and hepatic hypertrophy
(enlarged liver cells) occur within a few
days, usually reaching a steady-state within
two weeks, and persist as long as the chemi-
cal treatment continues.
Peroxisome proliferators are nongenotox-
ic carcinogens, which, unlike genotoxic car-
cinogens, do not directly damage DNA.
Rather, they alter gene expression via biologi-
cal effects. In the liver, forexample, nongeno-
toxic carcinogens may cause hepatomegaly
through their action on endo-
plasmic reticulum, by increasing
the number of peroxisomes,
and/or by increasing the number
of mitochondria. Many non-
genotoxic carcinogens are now
being identified. Many of them
have no detectable effects in
short-term tests for genotoxicity,
yet they cause malignant tumors
in rodents in long-term experi-
ments.
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"active oxygen" hinhe as a ular
mechanism to link peroxisome pr ifera-
tors to hepatocarcinogenicity. This
hypothesis suggests that the cells are over-
challenged by peroxisome proliferators in
the following way. Peroxisome prolifera-
tors stimulate increases in peroxisomal
beta-oxidation. The beta-oxidation system
may become 15- to 25-fold more active,
while catalase production, though stimu-
lated, is minimally affected (2- to 3-fold).
In the peroxisomal membrane, long-chain
fatty acids are oxidized, ultimately yielding
hydrogen peroxide. Within the peroxi-
some, hydrogen peroxide is normally
detoxified by catalases, but if hydrogen
peroxide were to escape the peroxisome,
toxicity may result. Oxygen radicals from
hydrogen peroxide in vitro can induce sev-
eral responses including lipid peroxidation,
membrane damage, and accumulation of
lipofuscin. Oxidative damage to DNA
could ultimately initiate tumorigenesis. To
date, however, only lipofuscin accumula-
tion has been consistently shown to sup-
port the oxidative stress hypothesis.
Cellproliferation. Liver size increases
dramatically in rodents after exposure to
many peroxisome proliferators. In addition
to hepatic hypertrophy, hepatocellular repli-
cation is responsible for much of the
increase, through a self-limiting and transient
process that occurs during the early stages of
exposure. During the first week after expo-
sure to most peroxisome proliferators, the
cell replication rate may increase dramatically
but soon returns to its baseline rate. Higher
G doses ofsome peroxisome pro-
g liferators, such as the experi-
mental drug Wy-14,643, may
_ be the exception, where cell
turnover maypersist.
According to Reddy and
his colleague, Sambasiva Rao,
this early cell proliferation
_ caused by peroxisome prolifer-
ators is a mitogenic response
and may be less carcinogenic
than cytotoxic, regenerative-
knimal data is type cell division. They report
:an't extrapo- that the average latency period
humans. between exposure and occur-
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mas ranges from 50 to 120
weeks in rodents. Animals
exposed to potent peroxisome
proliferators such as ciprofibrate
develop tumors as early as 50
weeks after exposure, while
those exposed to weaker peroxi-
some proliferators such as
phthalate esters start developing
tumors by week 90. Recent
studies have shown that removal
of rodents from peroxisome
proliferator exposure, after the Dan Marsm
appearance ornificant riska
but before hepatocellular carci-
nomas appear, results in com-
plete tumor regression. "Tumor regression
such as this is consistent with the important
role played by tumor promotion and/or pro-
gression by peroxisome proliferators," says
Daniel Marsman, a pathologist at the
NIEHS.
The classic definition of chemically
induced carcinogenesis includes stages ofini-
tiation, promotion, and progression. There is
some question as towhether peroxisome pro-
liferators induce or promote cancer. "An
active area ofperoxisome proliferator investi-
gation is their role as cancer promoters," says
Marsman. "Peroxisome proliferators are not
DNA reactive and have not been shown to
act as initiators. Instead they may promote
lesions initiated by other chemicals or those
occurring spontaneously. The tumors
induced are the result ofa multistage process.
Continuous, long-term peroxisome prolifera-
tor exposure is often needed for carcinogenic
activity, unlike the one-shot, cancer-inducing
exposure ofmany directly mutagenic chemi-
cals. Corroboration oftumor regression stud-
ies by other scientists might indicate that
short-term exposure to peroxisome prolifera-
tors may not be a significant risk factor in
humans. What we may find instead is that
only high-dose repeated exposure to these
agentswould raisehuman risk."
Some scientists believe that the hyper-
plastic response and the associated tumor
promotion activity may become a better pre-
dictor of nongenotoxic hepatocarcinogenesis
than peroxisome proliferation because there
are so many unanswered questions regarding
the link between peroxisome proliferation
and neoplasia.
Peroxisome proliferator-activated
receptor. Other investigations into long-term
effects of peroxisome proliferators suggest
that factors other than oxidative injury orcell
proliferation may influence the carcinogenic-
ityofthese compounds.
The PPAR, recently isolated, doned, and
sequenced, may be associated with the for-
mer proposed mechanisms, or may represent
a separate mechanism of carcinogenesis. A
member of the steroid hormone receptor
an-
ay n
for hi
superfamily, these PPARs con-
E tain both a DNA-binding
domain and ligand-binding
domain. Activated by struc-
turally diverse peroxisome pro-
liferators or fatty acids, the
PPAR modulates gene expres-
sion. In in vitro experiments,
the PPAR regulates transcrip-
tion of genes responsible for
biochemical changes (inducing
peroxisomal enzymes responsi-
ble for beta-oxidation and cer- -Short-term tain microsomal enzymes)
lot be a sig- served in per umans. obsre n eoxisome prolif- erator-treated cells.
According to John Ashby
and colleagues at Zeneca Central Toxicology
Laboratory, if a peroxisome proliferator
bound directly to PPARs, then the com-
pound's potency could be determined by its
ability to activate these receptors. However,
peroxisome proliferators do not appear to
bind directly to PPARs, but rather indirectly
activate the receptors by influencing other
cellular components.
"Afewyears ago, therewas a lot ofexcite-
ment when PPAR was first identified," says
Marsman. "The marked increases in enzyme
activity and the rapid induction ofimmediate
to early oncogenes and cell proliferation may
fit with a receptor mode of action. So far,
however, we know PPAR to be involved pri-
marily in lipid metabolism, and it's still too
early to predict its full impact."
PPAR subtypes have been discovered as
well in humans, and two have been cloned.
Jack VandenHeuvel, assistant professor in
Pharmacology and Toxicology at Purdue
University, expresses this opinion, "Since
rodent and human PPARs are activated by
peroxisome proliferators, I believe that recep-
tor-mediated responses are going to be simi-
lar between the two species. As to risk assess-
ment, it's hard to say at this time which
responses are relevant to carcinogenesis.
Once we identify the genes responsible for
the carcinogenic process and identify those
under direct PPAR control, we'll be able to
bridge that gap."
Rodents at Risk
"We know that compounds that cause per-
oxisome proliferation in rodent liver also
cause cancer in rodent livers," says William
Kluwe, director of toxicology at Pfizer
Laboratories. "Whether or not this can be
extrapolated to cancer in man is the heart
of the issue." According to Kluwe, peroxi-
somes that can be induced in vitro in
rodent hepatocytes cannot be replicated in
vitro in human hepatocytes, leading some
scientists to conclude that peroxisome pro-
liferation is not a significant human
response. However, studies show that the
link between peroxisome proliferation and
liver cancer is not a confirmed cause-and-
effect relationship. Another entirely differ-
ent mechanism that also happens to gener-
ate peroxisomes may be at work. This nei-
ther supports nor precludes the concept of
using peroxisome proliferation as a surro-
gate predictor ofcancer risk.
Reddy and colleagues originally
described the hepatocarcinogenic effect of
nafenopin in mice in 1976. Soon after, sev-
eral reports appeared in the literature estab-
lishing peroxisome proliferators as complete
liver carcinogens in rodents. Chronic feed-
ing ofperoxisome proliferators to rats caus-
es the following liver lesions to appear in a
sequential fashion: altered areas, hepatocel-
lular adenomas, and finally hepatocellular
carcinomas.
According to Ashby, there is an 81%
correlation between chemicals that induce
peroxisome proliferation in laboratory ani-
mal livers in the short term and those that
induce hepatocellular tumors in those ani-
mals over the long term. However, peroxi-
some-proliferating carcinogens vary widely
in their potency and effectiveness. Ashby
compared the potency and carcinogenic
effectiveness of ciprofibrate, diethylhexyl
phthalate (DEHP), tibric acid, methyl
clofenapate, nafenopin, and Wy-14,643 in
the F344 male rat. The highly effective
hepatocarcinogen ciprofibrate, at a low
dosage of 300 parts per million (ppm),
induced a high incidence oftumors. At the
other end ofthe spectrum, DEHP required
a dose of 12,000 ppm to produce tumors.
Tumor latency period, an additional
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potency indicator, was not reported for
DEHP because ofinsufficient data. Results
indicate that potent peroxisome prolifera-
tors (those inducing at least a sixfold
increase in hepatic peroxisomes) are also
highly effective liver carcinogens. The
DEHP study also demonstrates a good rel-
ative association between carcinogenesis
and peroxisome proliferation. F344 rats
fed 12,000 ppm DEHP had a tumor inci-
dence of24% and a 5-fold increase in per-
oxisomes. At a dose of 20,000 ppm, the
figures were 78% and 7-fold, respectively.
"This suggests that perhaps only a small
induction of peroxisomes is necessary to
produce tumors in this strain [of rat],"
Ashby and colleagues report.
Rodents are particularly susceptible to
peroxisome proliferation, but evidence indi-
cates that other species such as the guinea
pig, marmoset, and humans are much less
susceptible. Gordon Gibson of the
University of Surrey's School of Biological
Sciences writes in an article in Toxicology
Letters, "Much controversy exists as to
species differences in susceptibility to the
hepatocarcinogenicity of peroxisome prolif-
erators, with obvious implications for
human risk assessment."
Predicting Human Hazard
"If we could understand the mechanistic
process of peroxisome proliferators in
rodents, we could look for similar processes
in humans," says Ronald Melnick, a senior
toxicologist at the NIEHS. "That would
give us a stronger foundation for evaluating
human risk."
Popp declared at the 1990 Toxicology
Forum, "It doesn't do us any good to con-
tinue to study a particular phenomenon in
rodents and be able to study it to the nth
degree if we cannot make a transition of
that data over to humans. I think in this
particular case the use of human hepato-
cytes is extremely important in taking our
rodent toxicology data and trying to under-
stand what it means for man."
Comparative in vitro studies in human,
guinea pig, hamster, and rat hepatocytes are
underway. Although enzyme
induction has been the primary
focus thus far, the studies reaf-
firm relatively little, if any,
response of human hepatocytes
to peroxisome proliferators, con-
cedes Penelope Fenner-Crisp,
acting deputy director at EPA's 7<
Office ofPesticide Programs.
In the early literature, a few
studies examined human liver
biopsies from people who had
received hypolipidemic drugs in WilliamKit the past. One qualitative study of tant to con
nine patients who had taken tors known
gemfibrozil demonstrated no cancers.
increase in peroxisomes. A quantitative study
of 16 patients who had taken clofibrate
found a 50% increase in the number oftheir
hepatocyte peroxisomes. Cliff Elcombe, of
Zeneca's Central Toxicology Laboratory,
reported to the Toxicology Forum in 1990
that "some of these observations are ques-
tionable because peroxisomes have a half-life
of about 36 hours. Once the peroxisome-
inducing agent is stopped, peroxisome levels
rapidly return to baseline levels."
Elcombe claims that hepatocyte culture
systems eliminate problems ofabsorption of
these agents from the gastrointestinal tract.
At the forum, he related results from a
study investigating hepatocyte cell cultures
from the rat, guinea pig, marmoset, and
humans. Maintained for four days in the
presence of methylcofenapate, one of the
most potent proliferators known, and using
palmitoyl CoA oxidation as a peroxisomal
enzyme marker, these cultures yielded a
dose-related increase in the enzyme (more
than 1500%) in rats, whereas enzyme activ-
ity in guinea pig, marmoset, and human
cells was negligible.
William Stott, a toxicologist at Dow
Chemical, says that peroxisome proliferators
do not represent a potential carcinogenic
threat to humans. Basic genotoxicity tests of
many chemicals that cause peroxisome pro-
liferation demonstrate that these agents do
not cause DNA damage. Instead, their
tumorigenic effects on the liver appear to be
a secondary phenomenon to changes the
proliferators induce such as cell prolifera-
tion. According to Stott, peroxisome prolif-
erators generate a short burst of cell prolif-
eration in rodents, called a true mitogenic
wave of proliferation. "You don't see that
happening in higher mammalian cells," he
said.
Stott continues, "Changes such as per-
oxisome proliferation and increased cell
proliferation are necessary for tumors to
form. Without these effects, you don't get
tumors. Long-term epidemiology studies in
monkeys indicate that on exposure to per-
oxisome proliferators, their livers are less
sensitive to these compounds than seen in
rodents."
Kluwe says it is impor-
tant to concentrate on factors
c known to cause human can-
cers, such as direct damage to
DNA. "Results from studies
looking for DNA damage in
rodents are contradictory,"
states Kluwe. "Most of them
suggest that there is no evi-
dence of DNA damage by
chemicals that induce peroxi-
luwe
ncer
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.-Iti impor- some proliteration, even in
itrate on fac- rodents. Nonetheless, we still
cause human don't understand why rats
get liver tumors; if it is not
because of DNA damage, then what causes
the tumors?"
Long before we knew what a peroxi-
some was, we were investigating potential
carcinogenicity in chemicals," Kluwe con-
tinues. "Peroxisomes are supposed to be a
shortcut. Rather than spending three years
and lots of money to see if a compound
caused liver cancer, we hoped a two-week
study on 20 animals would give us the
answer. So far, there are no shortcuts.
Besides, looking at a single parameter and
trying to decide if a chemical is a true car-
cinogenic risk based on that information is
naive.
The Puzzle Persists
The controversy over the risk ofperoxisome
proliferators to humans continues. Ac-
cording to George Lucier of the NIEHS,
"the use of mechanistic data is an emerging
issue in risk assessment that's becoming
increasingly compelling. There is an indus-
try-wide push to develop strategies to identi-
fy which animal carcinogens may not be car-
cinogens in humans. The peroxisome prolif-
erators are one important aspect ofthat issue.
Mechanistic data would help considerably in
our evaluations of this issue. In the absence
of evidence that humans are not responsive,
it is prudent to assume that rodent carcino-
gens pose a health risk to humans."
Part of the problem in defining human
risk assessment is obtaining in vivo data for
humans. Existing clinical data are difficult to
obtain because some of the data are propri-
etary and difficult to use because ofthe limit-
ed number ofhuman subjects.
Stott reports that investigations on the
toxic effects of peroxisome proliferators in
higher mammals, including man, are under-
way on autopsy material and in vitro hepato-
cytes. "We test for peroxisome proliferators
on a selected basis. Data from these investi-
gations, though not one ofour standard reg-
istration type studies, is useful during prod-
uct development. Ifa compound we want to
register induces peroxisome proliferation, it's
a fair bet we're going to get liver tumors in
mice or rats. This data is only one piece of
information that goes in thejudgment call of
whether development on the product contin-
ues or we look for a compound that has a
similar efficacy but does not induce peroxi-
some proliferation."
Pharmaceutical and chemical companies
alike report that they try to avoid developing
products that induce peroxisome prolifera-
tion because of regulatory issues. The U.S.
regulatory agencies have not yet deemed per-
oxisome proliferators a class of chemicals
harmless to man. Peroxisome proliferators do
not enjoy the status ofchemicals that bind to
alpha-2.-globulin, a process which is known
to cause kidney cancer in male rats but is
considered irrelevant to humans.
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Nonetheless, there is strong feeling on
one side of the scientific community that
studies on peroxisome proliferators suggest
no hazard to humans. "It should be recog-
nized that a large body of existing data
demonstrates clearly that human [hepato-
cytes] are resistant to chemically induced per-
oxisome proliferation," says Elcombe. "This
suggests that peroxisome proliferation data,
and consequential tumor data generated in
rats and mice with nongenotoxic peroxisome
proliferators, is inappropriate information to
use in human risk assessment. The latest
research suggests that subtle species differ-
ences in response to PPARs may explain the
observed species differences in response to
peroxisome proliferators."
Ashby and colleagues write, a November
1994 article in Human and Experimental
Toxicology, "Although the correlation of
peroxisome proliferation with hepatocarcino-
genesis is striking, the generic mechanism by
which this class of chemicals induces liver
tumors is still not understood. On the one
hand, it could be argued that until the pre-
cise mechanism by which peroxisome prolif-
erator-induced cancer is elucidated, it cannot
be concluded without doubt that this dass of
agents does not produce cancer by a mecha-
nism totally distinct from, and independent
of, peroxisome proliferation. A parallel exists
with other forms of nongenotoxic carcino-
genesis, such as rodent thyroid carcinogenesis
associated with elevated levels of thyroid-
stimulating hormone. In this example, the
mechanistic evidence is supportive of, but
does not provide conclusive proof of, the
absence ofhuman hazard."
"On the otherhand," Ashby
continues, "it could be argued
that as long as there are data to
support the association between
peroxisome proliferation and
related phenomena in the liver
and hepatocarcinogenesis then
the peroxisome proliferation
effect can, and should, be used i
to establish the hazard of this
class of agents to animals and
man." Jack Vande
Looking at the economic of peroxisor
effect ofthis controversial issue, in humans
Stott says, "Certain products the risk.
have not made it to market in
the United States because this issue has not
been resolved. AndAmericans are not enjoy-
ing the potential benefits ofthese products."
On the other end ofthe spectrum, in an
article in Critical Reviews in Toxicology,
Reddy and Lalwani conclude, "a peroxisome
proliferator carcinogenic in experimental ani-
mals, as with all chemical carcinogens . . .
should be grounds for considering such a
compound as a carcinogen irrespective ofthe
carcinogenic mechanism(s) involved."
VandenHeuvel supports this position:
"Just because we don't see an increase in the
number of peroxisomes in human cells fol-
lowing exposure to peroxisome proliferators,
we can't claim this negates human risk assess-
ment." As evidence VandenHeuvel states
that in rodent testis, even though increases
are not seen in peroxisomes, there is a signifi-
cant increase in Leydig cell tumors with
exposure to peroxisome proliferators. Says
VandenHeuvel, "Until we determine which
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genes are involved in the car-
cinogenic process, and how
they are impacted by peroxi-
some proliferators and PPARs,
I don't feel comfortable about
saying thatthere is no risk."
"Regulatory agencies need
to reach a consensus on han-
dling peroxisome proliferators
in terms ofhuman risk assess-
ment," Popp asserts, "setting
up guidelines on whether to
deal with them as a group or
address each chemical individ-
ually. Then we'll be ready to
look at the data and deter-
mine how to use it in risk assessment."
At a recent meeting ofthe International
Association of Research in Cancer (IARC)
in Lyon, questions relevant to the mecha-
nisms of peroxisome proliferation were
pondered. Although many issues remain
unresolved, a consensus report on how to
handle data revolving around peroxisome
proliferation is forthcoming. Hirohi
Yamasaki, unit chief of multistage carcino-
genesis at IARC, says, "I think we've
reached some reasonable conclusions.
When we evaluate chemicals that induce
peroxisome proliferation, for example, we
should evaluate them case-by-case rather
than grouping them as peroxisome prolifer-
ators and saying that as a group they are safe
or dangerous in rodents or humans."
Melnick intimates that the pieces ofthe
peroxisome puzzle are far from coming
together. "Currently, there is no evidence
that positively demonstrates peroxisome
proliferators cause liver tumors in humans.
However, a negative doesn't prove that it
doesn't do it; it only means that the effect
might not yet have been observed."
Marilyn Citron
Marilyn Citron is a freelance journalist in
Birmingham, Mississippi.
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